ライフサイエンスコーパス: beta-blocker

1 EMPHASIS-HF trial (ACE inhibitor or ARB and beta blocker).

2 terference from antihypertensive medication (beta-blockers).

3 xperienced >=1 breakthrough cardiac event on beta-blocker.

4 he world and Cmpd-15 is the first allosteric beta-blocker.

5 g (SDs 16 and 12), and 108 (56%) were taking beta blockers.

6 or angiotensin receptor blockers (ARBs) and beta blockers.

7 patients out of a total of 229 who received beta-blockers.

8 creased survival of patients on nonselective beta-blockers.

9 ved regardless of heart rhythm or receipt of beta-blockers.

10 29.36%) were exposed to regular preoperative beta-blockers.

11 nditionally recommend the use of in-hospital beta-blockers.

12 rapy for select patients who do not tolerate beta-blockers.

13 ators, corticosteroids, benzodiazepines, and beta-blockers.

14 compared with placebo were as follows: 1991: beta-blockers, 4.01 (CrI, 0.48 to 7.43); 1995: alpha2-ad

15 placebo was greater in patients receiving a beta blocker (-5.76 mm Hg [95% CI -10.28 to -1.23]) or a

16 blockers (66% versus 68%; P=0.04) and early beta-blockers (56% versus 60%; P=0.01).

17 or ARBs (99 [25%] vs 304 [23%], p=0.61) and beta blockers (57 [14%] vs 168 [13%], p=0.54).

18 on or dose increase were 6% for MRA, 10% for beta-blocker, 7% for ACEI/ARB, and 10% for ARNI; corresp

19 beta-arrestin bias to the efficacy of select beta-blockers, a specific beta-arrestin-biased pepducin

20 tigate patient prognosis and the efficacy of beta-blockers according to renal function using estimate

21 tivation: beta-adrenergic receptor blockers (beta-blockers), ACE (angiotensin-converting enzyme) inhi

22 patients were receiving target doses of MRA, beta-blocker, ACEI/ARB, and ARNI therapy, respectively.

23 beta-blockers act to block excessive catecholamine stimu

24 ation of 5 AMI admission therapies (aspirin, beta-blockers, acute reperfusion therapy, door-to-balloo

25 energic tone and modulated by treatment with beta-blockers; acute afterload stress induces a deeper i

26 We aimed to describe beta-blocker adherence, and predictors thereof, among pa

27 ], angiotensin receptor blockers [ARBs], and beta-blockers adjusted for blood pressure, statins adjus

28 The exposure of interest was beta-blocker administration initiated during the hospita

29 Exposure to beta-blockers after TBI was associated with a reduction

30 ort B received mavacamten, 2 to 5 mg/d, with beta-blockers allowed.

31 compared with placebo plus beta-blocker and beta-blocker alone.

32 er 100 person-years [py]) was not reduced by beta-blockers alone (1.37 per 100 py; p = 1.00), or in c

33 luded no active therapy in 47 (8%) patients, beta-blockers alone in 350 (58%) patients, implantable c

34 Second, we explored outcomes associated to beta-blocker among advanced CKD participants with preser

35 taminants (five antibiotics, an herbicide, a beta-blocker, an antidepressant, and an antineoplastic)

36 nzodiazepines, anxiolytics, antidepressants, beta-blockers, anaesthetic agents and analgesics; length

37 adjusted difference for the combined dose of beta blocker and ACE-I or ARB: +6% [+2%, +10%]).

38 investigations and appropriate initiation of beta blockers and angiotensin-converting-enzyme inhibito

39 tin prescriptions included male sex, filling beta-blocker and antiplatelet agent prescriptions, and a

40 y during exercise compared with placebo plus beta-blocker and beta-blocker alone.

41 fting was performed in a 4-year-old patient; beta-blocker and exercise restriction were recommended i

42 patients with HFrEF should be treated with a beta-blocker and one of an angiotensin receptor-neprilys

43 Among patients with heart failure, combined beta-blocker and renin-angiotensin antagonist medication

44 vestigate the association between the use of beta-blockers and 1-year mortality.

45 Standard treatments consider the use of beta-blockers and angiotensin-converting enzyme inhibito

46 7%, 18%, and 2%, whereas 91% and 54% were on beta-blockers and angiotensin-converting enzyme inhibito

47 nts with obstruction is medical therapy with beta-blockers and calcium antagonists.

48 Additionally, in 11 patients we withdrew beta-blockers and diuretics and used phenylephrine and a

49 y recommended treatment to prevent VRB using beta-blockers and ligation.

50 ideline-directed medical therapies including beta-blockers and mineralocorticoid receptor antagonists

51 We obtained information about use of beta-blockers and other medications through linkage with

52 on in randomized controlled trials comparing beta-blockers and placebo.

53 norepinephrine infusion rate and the use of beta-blockers and plasma cytokines was assessed in 195 p

54 ersus 25.5% [P=0.01], respectively), whereas beta-blockers and ranolazine were prescribed at similar

55 The prescribed dosages of beta-blockers and renin-angiotensin system inhibitors we

56 tors/angiotensin II receptor blockers (ARB), beta-blockers and statins are recommended after acute my

57 nd statins only, 1.17 (95% CI: 1.10 to 1.25) beta-blockers and statins only, 1.19 (95% CI: 1.07 to 1.

58 vailable data regarding potential effects of beta-blockers and/or ACE inhibitors in coexisting venom

59 -dimethyl-4-cyanoaniline (DMABN), sotalol (a beta-blocker) and sulfadiazine (a sulfonamide antibiotic

60 ambient thermal environment), pharmacologic (beta-blockers), and genetic (beta2-AR knockout mice) to

61 itors, angiotensin-receptor blockers (ARBs), beta blockers, and aldosterone antagonists in adults wit

62 cidate the efficacy of ACE inhibitors, ARBs, beta blockers, and aldosterone antagonists in patients w

63 itors, angiotensin receptor blockers (ARBs), beta blockers, and mineralocorticoid receptor antagonist

64 tensin receptor-neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist

65 zyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist)

66 zyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist,

67 treated with target doses of ACEI/ARB/ARNI, beta-blocker, and MRA.

68 ors/angiotensin receptor antagonists, use of beta-blocker, and smoking cessation counseling.

69 Receipt of aspirin, beta-blockers, and acute reperfusion therapy on admissio

70 Utilization of statins, beta-blockers, and angiotensin-converting enzyme inhibit

71 or angiotensin-converting enzyme inhibitors, beta-blockers, and calcium channel blockers (CCBs) were

72 y, and PPV for self-reported use of statins, beta-blockers, and calcium channel blockers were all 95%

73 Statins, beta-blockers, and calcium channel blockers were each re

74 me inhibitors/angiotensin receptor blockers, beta-blockers, and dual antiplatelet therapy, respective

75 me inhibitors/angiotensin receptor blockers, beta-blockers, and dual antiplatelet therapy.

76 oinflammatory conditions, hyperphosphatemia, beta-blockers, and epoetin.

77 e inhibitors, angiotensin-receptor blockers, beta-blockers, and mineralocorticoid-receptor antagonist

78 adeoffs in adherence to ACE inhibitors/ARBs, beta-blockers, and statins on survival among older peopl

79 o had prescriptions for ACE inhibitors/ARBs, beta-blockers, and statins, and survived >/=180 days aft

80 Exercise restriction, beta-blockers, and surgical intervention were discussed

81 lasses of medical therapy including statins, beta-blockers, angiotensin-converting enzyme inhibitors/

82 perator curve 0.75 [0.71-0.79]) added use of beta-blockers, antidepressants, QT-prolonging drugs, opi

83 or angiotensin-receptor blockers (ARBs), and beta blockers are similar for men and women with heart f

84 Recent data suggest that beta-blockers are associated with prognostic advantages

85 without heart failure (HF), it is unclear if beta-blockers are associated with reduced mortality.

86 Thus, current life-prolonging beta-blockers are contraindicated in patients with both

87 e and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to under

88 aine users with cardiac disease suggest that beta-blockers are not unsafe and that may be effective i

89 Angiotensin-converting enzyme inhibitors and beta-blockers are recommended first-line agents for hear

90 ta-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in

91 ambulatory monitoring, and restricted use of beta-blockers as first-line therapy.

92 ug classes (statins, antiglaucoma drugs, and beta blockers) as an approach to reducing confounding by

93 te a potential role for ghrelin in mediating beta blocker-associated hypoglycemia in susceptible indi

94 16; 95% CI: 0.04 to 0.55) and regular use of beta-blockers at 6-month follow-up (HR: 0.20; 95% CI: 0.

95 66; 95% CI: 0.47 to 0.92) and regular use of beta-blockers at 6-month follow-up (HR: 1.62; 95% CI: 1.

96 on, there was no reduction in mortality with beta-blockers at any level of eGFR.

97 e inhibitor/angiotensin receptor blocker, or beta-blocker) at baseline; these patients had 33% lower

98 Pivotal trials of beta-blockers (BB) and angiotensin converting enzyme inh

99 Beta-blockers (BB) have been traditionally associated wi

100 (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonis

101 or ARBs (angiotensin receptor blockers) with beta-blockers (BBs) alone or in addition to implantable

102 beta-Blockers (BBs) are mainstay therapy for heart failu

103 icenter study testing the effect of early IV beta-blockers before PPCI in a general ST-segment elevat

104 commended dose of ACE inhibitors or ARBs and beta blockers, but women showed approximately 30% lower

105 beta-Blockers, calcium channel blockers, and mineralocor

106 giotensin system as it did not replicate for beta-blockers, calcium channel blockers, or diuretics.

107 E inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diu

108 owed that propranolol, a commonly prescribed beta-blocker, can reduce MDSC immunosuppression and enha

109 e beta-adrenoceptor agonist isoprenaline and beta-blocker carvedilol, we designed and synthesized thr

110 Furthermore, beta-blocker carvedilol-mediated beta-arrestin-dependent

111 ortality was lower for patients who received beta-blockers compared with those who did not (4.9% vs.

112 predicted poor outcomes, and regular use of beta-blockers correlated with late survival and LV funct

113 angiotensin-converting enzyme inhibitors and beta-blockers could prevent trastuzumab-related cardioto

114 amined the effect of study drug according to beta-blocker dose (>/=50% and <50% of target dose) and a

115 or intolerance and the evidence behind using beta-blocker dose and heart rate as therapeutic targets.

116 o have been stable on a "maximally tolerated beta-blocker dose," but this definition and how to achie

117 ents more commonly were not receiving target beta-blocker dose.

118 ive of previouscoronary revascularization or beta-blocker dose.

119 these were treated with >=50% of the target beta-blocker dose.

120 dies, we investigated an association between beta-blocker drug use with improved cancer-specific surv

121 Our results support the concept that beta-blocker drugs may improve the survival of PDAC pati

122 of light-at-night exposure and/or the use of beta-blocker drugs.

123 statins, renin-angiotensin system blockers, beta-blockers, dual antiplatelet therapy, and long-term

124 High-dose beta-blockers (eg, 100 mg of metoprolol succinate) admin

125 Endoscopic variceal ligation plus beta-blockers (EVL+BB) is currently recommended for vari

126 r angiotensin-converting enzyme inhibitor or beta-blockers experienced fewer interruptions in trastuz

127 ts were subdivided according to preoperative beta-blocker exposure status.

128 nd 85 years who had COPD to receive either a beta-blocker (extended-release metoprolol) or placebo.

129 unctive therapies, such as pretreatment with beta-blockers, ezetimibe, and proprotein convertase subt

130 zide and thiazide-like diuretics compared to beta-blockers for improved BP management.

131 , 10 (29%) of 35 patients in the endoscopy + beta-blocker group, as compared to 0 of 37 (0%) patients

132 Beta-blockers had no effect on mortality in patients wit

133 vedilol, a currently prescribed nonselective beta-blocker, has been classified as a beta-arrestin-bia

134 sease; however, current clinically available beta-blockers have poor selectivity for the cardiac beta

135 be harmful in HF, beta-adrenergic blockers (beta-blockers) have consistently been shown to reduce mo

136 iabetes mellitus and anemia, be treated with beta-blockers, have higher ejection fraction, relative w

137 eveal a significant mortality advantage with beta-blockers; however, quality of evidence is very low.

138 r for patients in sinus rhythm randomized to beta-blockers (HR: 0.73 vs. placebo; 95% CI: 0.67 to 0.7

139 To determine if beta-(beta)-blockers improve outcomes after acute traumatic br

140 published reports on the mechanisms by which beta-blockers improve clinical outcomes.

141 mmendations (42% for ACE-Is or ARBs, 29% for beta blockers in 2014) and was largely unchanged beyond

142 e optimal dose of ACE inhibitors or ARBs and beta blockers in patients with HFrEF.

143 The Beta-Blockers in Heart Failure Collaborative Group perfo

144 Adherence to beta-blockers in LQTS is suboptimal in half of those wit

145 rt the strategic use of clinically available beta-blockers in patients to improve responses to immuno

146 s, suggesting limited additional benefit for beta-blockers in patients who were adherent to statins a

147 stream repressors of miR-1 as treatment with beta-blockers in pressure-overloaded mouse hearts preven

148 ummarize the current knowledge on the use of beta-blockers in pulmonary hypertension.

149 slight differential increases in the PDC for beta-blockers in the 2012 entry cohort (adjusted differe

150 By analogy with the key role of beta-blockers in the management of left heart failure, s

151 nventional therapy (ACE inhibitor or ARB and beta blocker) in patients with chronic HFrEF by making i

152 te use of beta-adrenergic receptor blockers (beta-blockers) in the contemporary management of these c

153 Although beta-blockers increase survival in patients with heart f

154 nic treatment with carvedilol, but not other beta-blockers, indeed enhances contractile force in skel

155 from beta-blocker related side effects (ie, beta-blocker intolerance) in 56/64 patients (88%).

156 0%, type of surgery, and preoperative use of beta-blockers, intra-aortic balloon pump, or catecholami

157 ional stress, for which current therapy with beta-blockers is incompletely effective.

158 the renin-angiotensin-aldosterone system and beta blockers) is useful only when optimally implemented

159 The widespread occurrence of the beta-blocker labetalol causes environmental health conce

160 ociated breakthrough cardiac events while on beta-blockers, LCSD as 1-time monotherapy for certain pa

161 ance metastasis from primary tumors and that beta-blockers may be protective in breast cancer.

162 Observational studies suggest that beta-blockers may reduce the risk of exacerbations and d

163 and support the combination use of an ARNI, beta blocker, MRA, and SGLT2 inhibitor as a new therapeu

164 ase-modifying pharmacological therapy (ARNI, beta blocker, MRA, and SGLT2 inhibitor) versus conventio

165 Patients who used beta-blockers (n = 522) had a lower cancer-specific mort

166 ngiotensin-aldosterone system inhibitors and beta-blockers, n = 20).

167 one system inhibitors, n = 20; withdrawal of beta-blockers, n = 20; and withdrawal of renin-angiotens

168 ce cautions against the use of non-selective beta-blockers (NSBB) in patients with refractory ascites

169 Nonselective beta-blockers (NSBB), isosorbide-mononitrate (ISMN), car

170 The safety of nonselective beta-blockers (NSBBs) in advanced cirrhosis has been que

171 uch therapy has been the use of nonselective beta-blockers (NSBBs) that act by reducing portal venous

172 Treatment of TBI patients with beta-blockers offers a potentially beneficial approach.

173 The effect of beta-blockers on amblyopia was not adequately documented

174 or being adherent to ACE inhibitors/ARBs and beta-blockers only, 0.98 (95% CI: 0.91 to 1.07) for ACEI

175 s/ARBs only, 1.32 (95% CI: 1.21 to 1.44) for beta-blockers only, 1.26 (95% CI: 1.15 to 1.38) statins

176 SHIFT type (P=0.421) were receiving selected beta-blockers, only 58.8% and 67.3% (P<0.001) were on >5

177 excluded patients who were already taking a beta-blocker or who had an established indication for th

178 Patients receiving beta-blockers or angiotensin-converting enzyme inhibitor

179 t follow-up, 128 (45%) patients were only on beta-blockers or no treatment, 41 (15%) were on sotalol

180 If medical treatment is selected, either beta-blockers or nondihydropyridine calcium channel bloc

181 months of treatment with ACE inhibitor, ARB, beta blocker, or aldosterone antagonist.

182 rho = -0.43, P = 0.003), and treatment with beta-blockers (P = 0.001).

183 aspirin (p < 0.001), statin (p < 0.001), and beta-blockers (p = 0.002).

184 this ionization source is demonstrated using beta-blockers, peptides, and proteins.

185 The cationic beta-blocker pindolol was injected electrokinetically, a

186 The beta-blocker positive group had significantly better sur

187 c assessment (OR, 0.79 [95% CI, 0.66-0.94]); beta-blocker prescription (OR, 0.70 [95% CI, 0.55-0.90])

188 itive protein phosphatase 1 and decreased by beta-blocker pretreatment.

189 mode of action through co-treatment with the beta-blocker propranolol, while leaving the peripheral e

190 vention of adrenergic-induced arrhythmias by beta-blockers (propranolol and carvedilol), flecainide,

191 No clear rate differences were observed by beta-blocker receptor selectivity.

192 beta-Blockers reduce mortality and improve symptoms in p

193 Regardless of pre-treatment heart rate, beta-blockers reduce mortality in patients with heart fa

194 It is unknown if beta-blockers reduce mortality/morbidity in patients wit

195 angiotensin-converting enzyme inhibitors or beta-blockers reduce the rate of trastuzumab-induced car

196 In 13,861 patients in sinus rhythm, beta-blockers reduced mortality versus placebo; adjusted

197 Beta-blockers reduced ventricular rate by 12 beats/min i

198 n unacceptable quality of life stemming from beta-blocker related side effects (ie, beta-blocker into

199 get for beta-adrenergic antagonists, such as beta-blockers, relatively little is yet known about its

200 beta-Blockers remain essential in the treatment of HFrEF

201 <95 mm Hg receive more often triple therapy (beta-blocker, renin-angiotensin system inhibitor, and mi

202 nhibitors/angiotensin receptor blockers, and beta-blockers, respectively.

203 , 88,542 (96.4%) and 81,933 (93.2%) received beta-blockers, respectively.

204 In both groups, HVPG and acute beta-blocker response were evaluated at baseline and HVP

205 Celiprolol, a barely studied beta-blocker, revealed the most distinct EFr among all i

206 antiplatelets (RR=0.83; 95% CI, 0.75-0.91), beta blockers (RR=0.96; 95% CI, 0.91-0.99), coronary ang

207 unities, with no patients on target doses of beta-blocker, sacubitril/valsartan, and mineralocorticoi

208 trial of patients with CPVT, flecainide plus beta-blocker significantly reduced ventricular ectopy du

209 before and after treatment with amiodarone, beta-blockers, sotalol, or ablation.

210 nists, diuretics, stimulants, narcotics, and beta-blockers) spiked in human urine and plasma samples.

211 ndary prevention medications (antiplatelets, beta-blockers, statins, and renin-angiotensin-aldosteron

212 ed lower doses of ACE inhibitors or ARBs and beta blockers than men, and brings into question what th

213 nicians actively initiating and up-titrating beta-blockers that may aid in achieving maximally tolera

214 For cationic beta-blockers the theoretical plates achieved in the cap

215 ications for development of more efficacious beta-blocker therapies.

216 added to beta-blocker therapy is superior to beta-blocker therapy alone for the prevention of exercis

217 nts >=65 years of age with MI, discharged on beta-blocker therapy and alive 3 years later without a r

218 ts with FBN1 pathogenic variants who receive beta-blocker therapy and who limit strenuous exercise, a

219 ncreased the risk of recurrent SCAD, whereas beta-blocker therapy appeared to be protective.

220 ity of SCAD patients were taking aspirin and beta-blocker therapy at discharge and at follow-up.

221 raction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately se

222 ing these receptors is part of the basis for beta-blocker therapy for heart failure.

223 ey potentially offer a truly cardioselective beta-blocker therapy for the large number of patients wi

224 (odds ratio [OR], 0.94 [95% CI, 0.69-1.27]), beta-blocker therapy if prior myocardial infarction or l

225 enefit for antiplatelet, lipid-lowering, and beta-blocker therapy in both the CABG and PCI groups (P=

226 d clinical study that examines the impact of beta-blocker therapy in patients with dystrophinopathies

227 Although beta-blocker therapy is standard for most patients, conc

228 ide dosed to therapeutic levels and added to beta-blocker therapy is superior to beta-blocker therapy

229 ise test while receiving maximally tolerated beta-blocker therapy that was continued throughout the t

230 beta-blocker therapy while highly effective for heart fa

231 nt may provide added therapeutic efficacy to beta-blocker therapy.

232 D see a cardiovascular specialist or receive beta-blocker therapy.

233 bitors and angiotensin II receptor blockers, beta-blockers, thiazide diuretics, calcium channel block

234 hyrotoxicosis are monitored and treated with beta-blockers to control symptoms given that most of the

235 ty and efficacy of both topical and systemic beta-blockers to promote regression of periocular hemang

236 ly replicated SNPs were further validated in beta-blocker treated participants from PEAR-2 and PEAR f

237 er validated for opposite association in two beta-blockers treated cohorts from PEAR-2 metoprolol (p

238 Of the 88 carriers, 93% met criteria for beta-blocker treatment and 5/88 (5.7%) were on medicatio

239 s encompassing 2005 unique TBI patients with beta-blocker treatment and 6240 unique controls.

240 We aimed to investigate associations between beta-blocker treatment and cardiovascular outcome and mo

241 variceal ligation (EVL) or glue injection + beta-blocker treatment was compared with TIPS placement

242 MINOCA, a trend toward a positive effect of beta-blocker treatment, and a neutral effect of dual ant

243 ological response to adrenergic agonists and beta-blocker treatment.

244 rate <60-30 mL/min per 1.73 m(2)), for whom beta-blocker trials demonstrate benefit.

245 is a survival benefit in patients exposed to beta-blockers undergoing non-cardiac surgery.

246 was used to compare event rates according to beta-blocker usage status.

247 per week, 561 [52.8%]; P < .001), and lower beta-blocker use (73 [6.9%]; P < .001) compared with low

248 en examined the adjusted association between beta-blocker use (and dose) at 3 years and the cardiovas

249 in mortality between those with and without beta-blocker use (average treatment effect [ATE] coeffic

250 tes mellitus type II (OR, 4.1, P=0.046), and beta-blocker use (OR, 3.8, P=0.049) in univariate regres

251 We used Part D data to calculate beta-blocker use after discharge and beta-blocker use ov

252 ars later without a recurrent MI to evaluate beta-blocker use and dose (none, <50%, and >=50% of the

253 (beta-Blocker Use and Mortality in Hospital Survivors of

254 udy was to determine the association between beta-blocker use and mortality in patients with AMI with

255 The association between beta-blocker use and outcomes were analyzed using Poisso

256 Of the 6893 patients >=65 years age, beta-blocker use at 3 years was 72.2% (n=4980); 43% (n=2

257 The benefit of beta-blocker use beyond 3 years after a myocardial infar

258 In this observational analysis, beta-blocker use beyond 3 years post-MI, regardless of t

259 ncreased (hazard ratio: 2.46; p = 0.011) and beta-blocker use diminished (hazard ratio: 0.36; p = 0.0

260 or cancer-specific mortality associated with beta-blocker use during the 90-day period before cancer

261 unctional outcome, and quality of life after beta-blocker use for TBI.

262 ies are needed to characterize the extent of beta-blocker use in CAD and heart failure, and how evide

263 iew examines the current evidence supporting beta-blocker use in heart failure with preserved ejectio

264 Preoperative beta-blocker use is strongly associated with improved su

265 lculate beta-blocker use after discharge and beta-blocker use over time.

266 e antiinflammatory cytokine balance, whereas beta-blocker use was associated with a more proinflammat

267 rget dose) nor high dose (>=50% target dose) beta-blocker use was associated with a significant diffe

268 Although systemic beta-blocker use was associated with lower IOP and syste

269 Among patients with HFrEF, beta-blocker use was associated with lower risk of death

270 Systemic beta-blocker use was independently associated with an IO

271 beta-blocker use was not associated with a significant d

272 We first explored associations between beta-blocker use, 5-year death, and the composite of car

273 t, macroalbuminuria, higher mean pulse rate, beta-blocker use, and sustained albuminuria.

274 e rate, higher mean systolic blood pressure, beta-blocker use, estimated glomerular filtration rate <

275 The role of prolonged beta-blocker use, particularly in older adults, needs fu

276 o did not have an established indication for beta-blocker use, the time until the first COPD exacerba

277 arcinoma diagnosis, presence of ascites, and beta-blocker use.

278 ant difference in risk when compared with no beta-blocker use.

279 higher risk of stroke (1.0% vs 0.5% without beta-blocker use; P = .005) and mortality (3.1% vs 2.3%

280 = .005) and mortality (3.1% vs 2.3% without beta-blocker use; P = .03) and should not be routinely u

281 no significant association was observed for beta-blocker users in advanced CKD with HFpEF (death: 0.

282 ltiorgan failure were significantly lower in beta-blocker users, as were the incidences in postoperat

283 otensin-aldosterone system inhibitors and/or beta-blockers versus continuation of treatment.

284 ting a total of 187 patients; treatment with beta blocker was the intervention that could not be anal

285 d up-titration of ACE inhibitors or ARBs and beta blockers was encouraged by protocol.

286 In contrast, use of beta-blocker was not associated with an improved 30-day

287 examine the influence of healthy user bias, beta-blocker was used as an active comparator.

288 HFrEF patients with advanced CKD, the use of beta-blockers was associated with lower morbidity and mo

289 LVSD as recorded in the hospital, the use of beta-blockers was not associated with a lower risk of de

290 eptor blockers, calcium channel blockers, or beta blockers) was significantly better than thiazides a

291 28%; 41% women; 13% African American; 65% on beta-blockers) was assembled.

292 beta blockers were inferior to other drugs for the preve

293 l propranolol, but intralesional and topical beta-blockers were also used.

294 beta-Blockers were consistently shown to reduce astigmat

295 beta-Blockers were generally well tolerated and had mild

296 n (odds ratio, 1.79; P=0.007) while those on beta-blockers were less likely to have low sPAT ratio (o

297 s mimics the hypertrophy seen with broad TGF-beta blockers, while avoiding the adverse effects due to

298 t, no difference in adverse events comparing beta-blockers with placebo, and higher mortality in pati

299 observed for both ACE inhibitors or ARBs and beta blockers, with women having approximately 30% lower

300 atment failure with 1 antiarrhythmic drug or beta-blocker, with 4-year follow-up.